Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia, Myeloid, Acute × talazoparib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 12 Prostatic Neoplasms 9 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Endometrial Neoplasms 3 Small Cell Lung Carcinoma 2 Fallopian Tube Neoplasms 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1

Interventions

venetoclax 176 Azacitidine 147 Cytarabine 115 fludarabine 85 Cyclophosphamide 73 Specimen Handling 56 fludarabine phosphate 50 Daunorubicin 49 Decitabine 45 Whole-Body Irradiation 40 Biopsy 40 Mycophenolic Acid 36 Injections 35 Idarubicin 35 Tacrolimus 32 Granulocyte Colony-Stimulating Factor 31 Busulfan 31 Melphalan 30 Stem Cell Transplantation 27 gilteritinib 24 Filgrastim 23 CPX-351 23 Peripheral Blood Stem Cell Transplantation 20 decitabine and cedazuridine drug combination 19 Mitoxantrone 19 Etoposide 19 Cladribine 18 ivosidenib 17 Gemtuzumab 17 enasidenib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05101551 2025-05-29

PARPAML

Stanford University

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡